PET monitoring of donepezil therapy in patients with Alzheimers

The 12th International Symposium on Radiopharmacolog

Positron emission tomographic measurement of acetylcholinesterase activity in Frontotemporal Dementia with Parkinsonism linked to Chromosome 17.

The Movement Disorder Society’s 8th International Ciongress of Parkinson’s Disease and Movement Disorders, Rome, June 13-17, 200

Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET

Acetylcholinesterase (AChE) activities in the brain of three patients with AD were measured once before and once during donepezil treatment (5mg/d in two patients, 3mg/d in one patient) using PET and N-[11C] methylpiperidin-4-yl acetae. Donepezil reduced K3 values,showed some degree of symptomatic improvement, and it was concluded that this improvement was likely caused by improved cholinergic activity by inhibition of AChE in the brain

Brain Acetylcholinesterase Activity in Alzheimer Disease Measure by Positron Emission Tomography

Brain acetylcholinesterase activity was measured in 14 patients with Alzheimer disease and 14 age-matched control subjects by positron emission tomography with a radioactive acetylcholine. Kinetic analysis was performed to calculate k3, an index of acetylcholinesterase activity. The k3 values were significantly reduced in the necortex, hippocampus, and amygdata of all patients with Alzheimer disease, suggesting a loss of cholinergic innervation from the basal forebrain. Most profound reductions of k3 values were observed in the temporal (-30%) and parietal cortices (-31%), although reductions of k3 values were relatively uniform in the cerebral neocortex. This technique may be a powerful tool for early diagnosis of Alzheimer disease and also for therapeutic monitoring of acetylcholinesterase inhibitors in Alzeimer disease

Brain Cholinergic Function in Dementia with Lewy Bodies and Alzheimers Disease

The 5th International Conference on Progress in Alzheimers and Parkinsons Diseas

Progressive Loss of Cortical Acetylcholinesterase Activity in Association with Cognitive Decline in Alzheimer\u27s Disease: A Positron Emission Tomography Study

We measured brain acetylcholinesterase activity in 30 patients with Alzheimer\u27s disease(AD) and 14 age-matched controls by positron emission tomography (PET) and using a carbon 11-labeled acetylcholine analogues. Seven AD patients had repeat PET scans. The k3 values were calculated as an index of acetylcholinesterase activity in a three-compartment analysis using the metabolite corrected arterial input function. Twenty-eight of the 30 AD patients (14 each in the early and late onset subgroups) were retained in the study so as to equalize the range and average severity of cognitive impairment within the early and late onset subgroups. The k3 values were significantly reduced in the neocortex, hippocampus, and amygdala in the early onset AD patients, although the k3 values were significantly reduced only in the temporopairetal cortex and amygdala in the late onset AD patients. In the longitudinal study, all 7 repeat AD patients showed further reduction of cortical k3 values in the second PET scans with a mean interval of 2 years, suggesting a progressive loss of the ascending cholinergic system from the nucleus basalis of Meynert in AD. In 37 AD patients, there was a highly significant correlation between the cortical k3 values and mini-Mental State Examination scores, supporting the cholinergic hypothesis in AD